GLP-1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice
An estimated 11% of Americans are currently taking GLP-1 drugs. Because the drugs, known as a treatment for diabetes and obesity, are widely studied, new research is revealing other, unknown, effects on the human body.
In a new study, the GLP-1 drug semaglutide was shown to extend lifespan in older, healthy mice. When the effects of the treatment were compared to those of caloric restriction, the drug mimicked the anti-aging benefits of calorie restriction, with greater benefits in some areas.
While GLP-1s have been found to delay the onset of many age-related diseases in animals, this new study in healthy older mice offers evidence that these drugs may slow physiological aging itself, a notion that could potentially tie the widespread benefits of GLP-1s to a common source.
This research is published inNaturein the paper, “Late-life semaglutide treatment slows ageing and extends lifespan in female mice.”
“Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see,” said Rafael de Cabo, PhD, a senior investigator at the NIH’s National Institute on Aging (NIA).
To understand the impact of GLP-1s at a time when the effects of aging are most pronounced, the study authors administered semaglutide to 20-month-old female mice for three months.
Compared with a control group, mice treated with the drug showed improved muscle and cognitive function. Gene expression analysis showed that several hallmarks of natural aging, such as increased inflammation and reduced regenerative capacity, were reduced in treated animals. Another group of mice treated until the end of life had a median lifespan nearly 100 days longer than that of untreated mice.
More specifically, “treatment of 20-month-old female C57BL/6 mice with the GLP-1R agonist semaglutide for three months improved physiological function, attenuated hallmarks of aging and modulated nutrient sensors and conserved genetic regulators of aging.”
The authors compared semaglutide with calorie restriction to see whether its benefits were simply due to reduced food intake or something else.
Over five months, scientists administered semaglutide to one group of 20-month-old female mice, while another group received a 24% calorie-restricted diet that matched the treated animals’ feeding pattern. The authors drew numerous parallels between the two groups, with most physiological measurements remaining stable. However, semaglutide-treated mice surpassed baseline levels in exploratory behavior, spatial memory, and blood-sugar maintenance. The groups also differed in metabolic rate, which was reduced in the calorie-restricted animals but largely unchanged in the semaglutide-treated mice.
“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction. Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions,” said Danica Chen, PhD, professor of metabolic biology and nutrition at UC Berkeley.
While these findings may guide future research, they do not imply that similar results could be achieved immediately in humans. Additional clinical studies, such as the recent post-hoc analysis of the SLIM LIVER trial, will be necessary to determine the clinical efficacy of GLP-1s on longevity in human patients.
Future clinical investigations may also explore benefits in healthy aged individuals, Chen explained, which would greatly broaden the application of GLP-1s.
NewsBehavioral geneticsDiabetesMiceObesityPeptidesSpatial genomicsPrevious article
Human Pancreatic Duct Cells Show Diabetes Therapy PotentialNext article
Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory EraAlso of Interest
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MiceRevvity Signs Agreement to Acquire Human Cell Design10 CDMO Up & Comers 2026Monoclonal Antibodies Targeting MMP-9 Alleviate Peripheral Neuropathy in Diabetic MiceThe Multi-Attribute Method (MAM) as a Biologics Lifecycle BackboneAnticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal MiceRelated Media
Omics in Orlando: A Video Report from AGBT, Day OneReporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDSun, Sequencing, and Spatial: Day One at AGBT 2025Sun, Spatial, and Sequencing: A Video Report from the First Day of AGBTYoung Scientist Creates Bandage Sensor for Wound HealingSmart Contacts Can Monitor the Glucose in TearsTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
